Grit Property Group

Grit Biotechnology develops next-generation tumor-infiltrating lymphocyte therapies and related immunotherapies targeting solid tumors. Its lead program GT101 will enter Phase II trials by late 2025. The pipeline includes genetically engineered TIL products such as GT201—now cleared by both Chinese and U.S. regulators to begin clinical trials—and next-gen candidates like GT316. The company leverages multiple proprietary platforms including CRISPR-based gene editing and advanced nanoparticle delivery systems. Recent scientific presentations highlight progress on APC-targeted mRNA cancer vaccines, nonviral nanoparticle-directed in vivo CAR-T therapies, and LNP-mediated gene editing approaches.